Genmab A/S (GMAB) Up 10.8% — Should I Fire on This Signal?
Genmab A/S (GMAB) delivered a breakout session this Monday, closing at $38.50 on the NASDAQ — a $3.75 gain that pushed the stock decisively into new territory. The close sits roughly 7.2% above the prior 52-week high of $35.91, a level set just days earlier on September 30, 2026. The stock has now climbed about 63% off the bottom of its 52-week range of $23.62, and Monday's move turned a steady recovery into a fresh high on a clinical catalyst.
Volume reached approximately 12.39 million shares, more than five times the 90-day average of roughly 2.29 million. Participation at that scale points to buyers re-rating the stock, not a thin-market drift higher.
Why Genmab A/S Price is Moving Higher
The catalyst was strong Phase 3 data. Genmab and AbbVie (ABBV) announced on October 5 that the EPCORE DLBCL-2 trial showed adding epcoritamab to standard R-CHOP chemotherapy reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients with International Prognostic Index scores of 2–5. The statistics were decisive, with a hazard ratio of 0.49, a 95% confidence interval of 0.36–0.67, and a p-value below 0.0001. The primary analysis in the higher-risk group, patients scoring 3–5, also showed a 51% risk reduction. That consistency matters because first-line DLBCL is a far larger market than the relapsed and refractory setting where epcoritamab, marketed as EPKINLY and TEPKINLY, is already approved. The combination remains investigational, and the companies said they will discuss next steps with regulators. That sets up a potential label expansion that could reshape the franchise's revenue profile.
Wall Street moved quickly to price in the broader pipeline story. Guggenheim raised its price target to $54 from $45 and reiterated its Buy rating, citing epcoritamab, Rina-S, and petosemtamab as drivers. The new target implies roughly 40% upside from Monday's close even after the rally. The epcoritamab readout also built on momentum from October 3, when Genmab reported Phase 2 results for rinatabart sesutecan (Rina-S) showing a 45.9% response rate among 109 ovarian cancer patients, with a median response duration of 12.1 months. Two positive late-stage data sets in three days handed investors a clear reason to reassess the company's growth runway.
The rally rests on a fundamental base that was already strengthening. Revenue reached $1.16 billion in the quarter ended June 30, up 29.5% from $896 million in the March quarter, and trailing revenue growth stands at 24.86%. Earnings per share sit at $6.24, and the stock trades at a forward P/E of just 5.57, a strikingly low multiple for a profitable oncology company with a deep partnered portfolio. The move was clearly company-specific. Thermo Fisher Scientific Inc. (TMO) gained 3.35%, while Merck & Co., Inc. (MRK) slid 3.30%, so Genmab's double-digit advance stood well apart from a mixed Health Care tape.
What is the Genmab A/S Rating - Should I Buy?
Weiss Ratings assigns GMAB a C+ rating. The rating was upgraded on 9/1/2026. Current recommendation is Hold. That upgrade came a month before Monday's data, so Weiss's framework was already registering improvement in the business before the latest clinical win. A C+ sits at the top of the Hold tier, which signals a risk/reward profile that is tilting favorably without yet clearing the bar for a Buy.
The balance sheet and the earnings engine are the core of the case. Genmab is rated Excellent on the Solvency Index, which reflects a company that funds a broad clinical pipeline from its own profits rather than from dilutive capital raises. That matters for a biotech advancing epcoritamab, Rina-S, and a slate of early-stage solid tumor candidates at the same time. The Good rating on the Efficiency Index points the same way. Royalty streams from partnered blockbusters such as DARZALEX allow Genmab to convert revenue into earnings at a rate most mid-cap biotechs cannot match, as $6.24 in EPS against a $20.30 billion market cap shows.
Where the picture becomes more nuanced is growth and shareholder experience. The Growth Index is rated Fair despite 24.86% revenue growth and a 29.5% sequential jump. Those numbers are solid, but much of Genmab's revenue depends on partner-marketed products, and the transition toward wholly owned commercial drugs is still under way, which helps explain why the rating is not higher. The Fair rating on the Total Return Index reflects a stock that only recently recovered from the $23.62 end of its 52-week range. The Weak Volatility Index captures the other side of a clinical-stage story: a 10.79% single-session jump on Phase 3 data shows how sharply this stock can reprice on binary trial outcomes in either direction.
Within the Health Care sector, Genmab sits alongside Thermo Fisher Scientific Inc. (TMO, C+) and ahead of Merck & Co., Inc. (MRK, C), Pfizer Inc. (PFE, C), and Gilead Sciences, Inc. (GILD, C). Outranking several of the sector's largest names shows how much ground Genmab's financial strength has gained relative to the broader pharmaceutical group.
About Genmab A/S
Genmab A/S (GMAB) is a Copenhagen-based company in the Health Care sector. It was incorporated in 1998 and develops antibody-based treatments for cancer and other serious diseases. Its commercial portfolio includes EPKINLY and TEPKINLY for adults with relapsed or refractory diffuse large B-cell lymphoma, large B-cell lymphoma, and follicular lymphoma, as well as Tivdak for recurrent or metastatic cervical cancer that has progressed on or after chemotherapy.
Much of Genmab's economic value comes from antibodies it created and licensed to major pharmaceutical partners. These include DARZALEX and DARZALEX FASPRO for multiple myeloma and light-chain amyloidosis, RYBREVANT for non-small cell lung cancer, TECVAYLI and TALVEY for relapsed or refractory multiple myeloma, Kesimpta for relapsing multiple sclerosis, and TEPEZZA for thyroid eye disease. Its collaborators include AbbVie, Pfizer, BioNTech, Johnson & Johnson, Bristol Myers Squibb, Lundbeck, Amgen, Novo Nordisk, and argenx, which gives Genmab royalty income across a wide range of therapeutic areas.
The pipeline extends that reach further. Epcoritamab is being developed across first-line DLBCL and follicular lymphoma, B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, Richter's syndrome, and pediatric B-cell cancers. Rinatabart sesutecan targets platinum-resistant ovarian cancer and other solid tumors, and acasunlimab is in development for non-small cell lung cancer. Earlier candidates GEN1059, GEN1055, GEN1057, and GEN1286 target advanced solid tumors. Genmab's competitive edge lies in its antibody engineering platforms, which have repeatedly produced molecules attractive enough to draw top-tier partners. That record gives the company proven scientific credibility and a diversified base of revenue to fund its push into owned commercial products.
Investor Outlook
Genmab A/S (GMAB) carries a Weiss Rating of C+ (Hold) and enters this new phase with a fresh 52-week high, a forward P/E of 5.57, and a first-line lymphoma opportunity that just gained compelling Phase 3 support. Investors should watch for the outcome of Genmab and AbbVie's regulatory discussions on epcoritamab plus R-CHOP, further progress for Rina-S in ovarian cancer, and whether the next quarterly report extends the 29.5% sequential revenue gain posted in the June quarter. See full rankings of all C+ rated Health Care stocks inside the Weiss Stock Screener.
--